Core Insights - Fortrea, a leading global contract research organization (CRO), is actively participating in key healthcare conferences in December 2025, showcasing its commitment to engaging with investors and stakeholders [1][2]. Company Overview - Fortrea (Nasdaq: FTRE) provides clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies to accelerate healthcare innovation [3]. - The company offers a range of services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging over three decades of experience across more than 20 therapeutic areas [3]. - Fortrea operates in approximately 100 countries, emphasizing a diverse and talented team to deliver agile solutions globally [3].

Core Insights - C4 Therapeutics, Inc. is participating in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, indicating its active engagement in the healthcare investment community [1][2] - The company focuses on advancing targeted protein degradation science to develop innovative medicines aimed at transforming patient outcomes [3] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker CCCC [3] - The company is dedicated to creating a new generation of medicines through targeted protein degradation, which aims to address difficult-to-treat diseases [3] - C4T utilizes its TORPEDO platform to design and optimize small-molecule medicines, enhancing the potential to overcome drug resistance and improve patient outcomes [3] Event Details - The fireside chat will take place on December 3, 2025, at 3:25 pm ET, with a live webcast available on the company's website [2] - An archived replay of the webcast will be accessible for approximately 90 days following the live event [2]

Company Overview - Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies using clinical insights [3] - The company owns global rights to develop and commercialize levosimendan, targeting the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension, for which no product has been approved to date [3] - Tenax Therapeutics' common stock is listed on The Nasdaq Stock Market LLC under the symbol "TENX" [3] Upcoming Events - The company will present at the 8th Annual Evercore Healthcare Conference on December 2, 2025, at 4:15 p.m. ET, featuring a fireside chat with Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer [1] - Additionally, Tenax Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 11:30 a.m. ET, also in a fireside chat format [2] - Live and archived webcasts of these presentations will be accessible from the company's investor relations webpage [2]

First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the launch of a new psilocybin longevity research initiative in collaboration with leading researchers in South Africa. This program positions Psyence BioMed as t ...

Core Insights - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [2] Company Overview - Upstream Bio is developing verekitug, the only known antagonist in clinical development targeting the receptor for thymic stromal lymphopoietin (TSLP), which is a key driver of inflammatory responses [2] - The company has advanced verekitug into separate Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD) [2] - Upstream Bio aims to address significant unmet needs for patients who are underserved by current standard care [2] Upcoming Events - Rand Sutherland, CEO of Upstream Bio, will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 4:30 p.m. ET [3] - The company will also be present at the 8th Annual Evercore Healthcare Conference on December 4, 2025, at 10:25 a.m. ET [3] - Live webcasts of these presentations will be available on Upstream Bio's website, with replays posted afterward [1][3]

ATHENS, Greece, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rubico Inc. (NASDAQ: RUBI) (the “Company”), an international owner and operator of modern, fuel efficient "ECO" tanker vessels, announced today that it entered into agreements with the time charterer of both its vessels to extend their time charter employment. Specifically, both vessels will continue earning a gross daily hire rate of $32,850 until 11 January 2027 and thereafter, and for 4 years, they earn a gross daily hire rate of $29,990. All other terms ...

Core Insights - The ALS Association has awarded Pasithea Therapeutics a grant of approximately $1 million to study PAS-004 in ALS patients, focusing on its efficacy, safety, and tolerability [1][2] - This grant marks the initiation of the first clinical trial of PAS-004 in individuals with ALS, which is a significant milestone for the company [2] - PAS-004 is a next-generation macrocyclic MEK inhibitor that has shown promising results in preclinical models and is currently being tested in other clinical trials for different conditions [2][3] Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company focused on developing PAS-004 for various diseases, including ALS, RASopathies, and MAPK pathway-driven tumors [3] - The company is conducting a Phase 1 clinical trial of PAS-004 in advanced cancer patients and a Phase 1/1b trial in patients with neurofibromatosis type 1 [3] ALS Association Overview - The ALS Association is the largest organization dedicated to ALS, funding research, providing support to patients and families, and advocating for better public policies [4] - The association's mission is to make ALS livable and ultimately find a cure for the disease [4] Disease Context - Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that leads to loss of motor function and is typically fatal within five years of diagnosis [5] - There is a significant unmet need for new therapies to address the functional deficits and progression of ALS [5]

Core Insights - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for oncology and autoimmune diseases [3] Company Overview - Nurix's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) [3] - The company is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline [3] - Nurix has partnered with Gilead, Sanofi, and Pfizer for drug discovery, retaining options for co-development and profit sharing in the U.S. [3] - The company utilizes an AI-integrated discovery engine and has expertise in ligase to enhance its clinical advancements [3] Upcoming Events - Arthur T. Sands, M.D., Ph.D., and Hans van Houte will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 [1] - The event will be webcast live and archived for 30 days [2]

Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines aimed at correcting abnormal gene expression to treat serious diseases [1][3] - The company will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, highlighting its focus on oncology and the potential of its Gene Traffic Control platform [1][2] Company Overview - Foghorn Therapeutics is engaged in discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system [3] - The company utilizes its proprietary Gene Traffic Control platform to systematically study, identify, and validate potential drug targets [3] - Foghorn is developing multiple product candidates specifically in the oncology sector [3] Event Participation - Management will participate in a fireside chat on December 4, 2025, at 9:10 a.m. EST, with a webcast available for 30 days [2][4] - The company will also engage in one-on-one meetings during the conference [4]

Core Insights - Kymera Therapeutics has initiated dosing in the BROADEN2 Phase 2b clinical trial for KT-621, targeting moderate to severe atopic dermatitis (AD), with data expected by mid-2027 [1][2] - The company is also set to launch the BREADTH Phase 2b trial for asthma in Q1 2026, indicating a strategic focus on multiple Type 2 diseases [3][2] - KT-621 is a first-in-class oral degrader of STAT6, which plays a crucial role in Type 2 inflammation, and has shown promising results in early studies [4][2] Company Developments - The BROADEN2 trial is a randomized, double-blind, placebo-controlled study involving approximately 200 patients over 16 weeks, with primary and secondary endpoints focused on efficacy and safety measures [2][1] - The completion of dosing in the KT-621 BroADen Phase 1b trial is anticipated to yield data in December 2025, further supporting the development timeline for KT-621 [1][2] - The parallel development of KT-621 for both AD and asthma is expected to enhance the drug's market potential and facilitate dose selection for future Phase 3 studies [3][2] Product Information - KT-621 is designed to degrade STAT6, a transcription factor involved in IL-4/IL-13 signaling, which is central to Type 2 inflammatory diseases [4][2] - The investigational drug has demonstrated complete STAT6 degradation in early trials, along with a favorable safety profile compared to placebo [4][2] - The potential market for KT-621 includes over 130 million patients globally suffering from various Type 2 diseases, highlighting significant unmet medical needs [4][2] Industry Context - Atopic dermatitis is a prevalent chronic inflammatory condition that significantly impacts patients' quality of life, with existing treatments showing limitations [5][2] - The ongoing development of innovative therapies like KT-621 reflects the industry's shift towards targeted treatments for chronic immunological diseases [6][2]